JP2017508466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508466A5 JP2017508466A5 JP2016555705A JP2016555705A JP2017508466A5 JP 2017508466 A5 JP2017508466 A5 JP 2017508466A5 JP 2016555705 A JP2016555705 A JP 2016555705A JP 2016555705 A JP2016555705 A JP 2016555705A JP 2017508466 A5 JP2017508466 A5 JP 2017508466A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- car
- seq
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000005754 cellular signaling Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403972A GB201403972D0 (en) | 2014-03-06 | 2014-03-06 | Chimeric antigen receptor |
| GB1403972.1 | 2014-03-06 | ||
| PCT/GB2015/050649 WO2015132604A1 (en) | 2014-03-06 | 2015-03-06 | Chimeric antigen receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508466A JP2017508466A (ja) | 2017-03-30 |
| JP2017508466A5 true JP2017508466A5 (enExample) | 2018-07-26 |
| JP6422134B2 JP6422134B2 (ja) | 2018-11-14 |
Family
ID=50554626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555705A Active JP6422134B2 (ja) | 2014-03-06 | 2015-03-06 | キメラ抗原受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10975162B2 (enExample) |
| EP (4) | EP3114147B1 (enExample) |
| JP (1) | JP6422134B2 (enExample) |
| KR (1) | KR101965040B1 (enExample) |
| CN (1) | CN106536563B (enExample) |
| AU (1) | AU2015225950B2 (enExample) |
| CA (1) | CA2941159C (enExample) |
| CL (1) | CL2016002196A1 (enExample) |
| DK (1) | DK3114147T3 (enExample) |
| ES (1) | ES2673123T3 (enExample) |
| GB (1) | GB201403972D0 (enExample) |
| HU (1) | HUE038625T2 (enExample) |
| MX (1) | MX360707B (enExample) |
| NZ (1) | NZ723471A (enExample) |
| PL (1) | PL3114147T3 (enExample) |
| PT (1) | PT3114147T (enExample) |
| RU (1) | RU2685479C2 (enExample) |
| SG (1) | SG11201606790XA (enExample) |
| TR (1) | TR201807939T4 (enExample) |
| WO (1) | WO2015132604A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| EP3184548A1 (en) * | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| CN109641012A (zh) | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| EP3604344A4 (en) * | 2017-03-27 | 2021-01-06 | Noile-Immune Biotech, Inc. | CHEMICAL ANTIGENIC RECEPTOR |
| CN118161496A (zh) | 2017-03-31 | 2024-06-11 | 小利兰·斯坦福大学托管委员会 | 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法 |
| CN107365798B (zh) * | 2017-07-13 | 2020-07-14 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用 |
| CN111164203A (zh) * | 2017-08-02 | 2020-05-15 | 奥托路斯有限公司 | 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞 |
| IT201800003464A1 (it) * | 2018-03-13 | 2019-09-13 | Ospedale Pediatrico Bambino Gesu | Cellule T CAR-CD30 per il trattamento di tumori CD30+ |
| US20210363217A1 (en) | 2018-06-19 | 2021-11-25 | Autolus Limited | Cell |
| WO2020018691A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Modified t cells and methods of their use |
| CN108864307A (zh) * | 2018-07-23 | 2018-11-23 | 北京多赢时代科技有限公司 | 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用 |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| GB201812474D0 (en) | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
| CN109136244A (zh) * | 2018-08-31 | 2019-01-04 | 河北璋达生物科技有限公司 | 一种可诱导凋亡的携带检测标签的cd20嵌合抗原受体t淋巴细胞及其应用 |
| CN109096405B (zh) * | 2018-09-20 | 2021-07-09 | 杭州普略生物科技有限公司 | 以gd2为靶点的嵌合抗原受体及药物组合物 |
| WO2020072705A1 (en) * | 2018-10-03 | 2020-04-09 | Nepenthe Biosciences, Llc | Anti-cd79 antibodies and their uses |
| JP2022523502A (ja) * | 2019-01-29 | 2022-04-25 | シャンハイ ジャオ トン ユニバーシティ | キメラ抗原受容体およびその使用 |
| CA3130671A1 (en) * | 2019-02-07 | 2020-08-13 | Board Of Regents, The University Of Texas Systems | Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| AU2020263495B2 (en) * | 2019-04-26 | 2025-09-25 | Allogene Therapeutics, Inc. | Rituximab-resistant chimeric antigen receptors and uses thereof |
| EP4008347B1 (en) * | 2019-08-01 | 2025-04-30 | Mie University | GD2-BINDING MOLECULE |
| US20220362299A1 (en) * | 2019-10-21 | 2022-11-17 | Purdue Research Foundation | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibiton techniques |
| US20220411535A1 (en) * | 2019-11-26 | 2022-12-29 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| AU2021252514B2 (en) * | 2020-04-06 | 2025-06-26 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2023139360A1 (en) | 2022-01-19 | 2023-07-27 | Autolus Limited | Nucleic acid construct |
| WO2023180511A1 (en) * | 2022-03-25 | 2023-09-28 | F. Hoffmann-La Roche Ag | Improved chimeric receptors |
| JP2025513245A (ja) * | 2022-04-18 | 2025-04-24 | ウィスコンシン アラムニ リサーチ ファンデーション | Ｃａｒ－ｍ細胞、ｃａｒ－ｎｋ細胞、ｃａｒ－ｅｏｓ細胞、及びｃａｒ－ｎ細胞を使用した併用免疫療法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| WO2025035762A1 (zh) * | 2023-08-15 | 2025-02-20 | 北京市眼科研究所 | 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用 |
| CN117024605B (zh) * | 2023-08-15 | 2024-01-09 | 北京市眼科研究所 | 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7449000A (en) * | 1999-09-30 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Human type complementation-determining domain transplanted antibody against ganglioside gd2 and derivative of this antibody |
| WO2004055056A1 (en) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| FR2906808B1 (fr) * | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| JP6029581B2 (ja) | 2010-06-19 | 2016-11-24 | メモリアル スローン−ケタリング キャンサー センター | 抗ｇｄ２抗体 |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| SG11201400527XA (en) * | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| CN103145849B (zh) | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| PL3071222T3 (pl) | 2013-11-21 | 2021-04-19 | Ucl Business Ltd | Komórka |
| KR102088082B1 (ko) | 2014-03-05 | 2020-03-11 | 유씨엘 비즈니스 리미티드 | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
-
2014
- 2014-03-06 GB GB201403972A patent/GB201403972D0/en not_active Ceased
-
2015
- 2015-03-06 EP EP15709320.4A patent/EP3114147B1/en active Active
- 2015-03-06 ES ES15709320.4T patent/ES2673123T3/es active Active
- 2015-03-06 CA CA2941159A patent/CA2941159C/en active Active
- 2015-03-06 PL PL15709320T patent/PL3114147T3/pl unknown
- 2015-03-06 DK DK15709320.4T patent/DK3114147T3/en active
- 2015-03-06 EP EP20169619.2A patent/EP3741778A1/en active Pending
- 2015-03-06 PT PT157093204T patent/PT3114147T/pt unknown
- 2015-03-06 CN CN201580011327.1A patent/CN106536563B/zh active Active
- 2015-03-06 RU RU2016138422A patent/RU2685479C2/ru active
- 2015-03-06 AU AU2015225950A patent/AU2015225950B2/en active Active
- 2015-03-06 SG SG11201606790XA patent/SG11201606790XA/en unknown
- 2015-03-06 JP JP2016555705A patent/JP6422134B2/ja active Active
- 2015-03-06 MX MX2016010643A patent/MX360707B/es active IP Right Grant
- 2015-03-06 NZ NZ723471A patent/NZ723471A/en unknown
- 2015-03-06 HU HUE15709320A patent/HUE038625T2/hu unknown
- 2015-03-06 KR KR1020167027554A patent/KR101965040B1/ko active Active
- 2015-03-06 TR TR2018/07939T patent/TR201807939T4/tr unknown
- 2015-03-06 US US15/123,331 patent/US10975162B2/en active Active
- 2015-03-06 EP EP17160533.0A patent/EP3241851A1/en not_active Withdrawn
- 2015-03-06 EP EP19167976.0A patent/EP3553091A1/en not_active Withdrawn
- 2015-03-06 WO PCT/GB2015/050649 patent/WO2015132604A1/en not_active Ceased
-
2016
- 2016-09-01 CL CL2016002196A patent/CL2016002196A1/es unknown
-
2021
- 2021-03-09 US US17/196,670 patent/US11879016B2/en active Active
-
2023
- 2023-11-21 US US18/515,458 patent/US20240301088A1/en active Pending